MX2020009403A - Compuestos con actividad anticancer. - Google Patents
Compuestos con actividad anticancer.Info
- Publication number
- MX2020009403A MX2020009403A MX2020009403A MX2020009403A MX2020009403A MX 2020009403 A MX2020009403 A MX 2020009403A MX 2020009403 A MX2020009403 A MX 2020009403A MX 2020009403 A MX2020009403 A MX 2020009403A MX 2020009403 A MX2020009403 A MX 2020009403A
- Authority
- MX
- Mexico
- Prior art keywords
- substituted azole
- suppress
- cell cycle
- diones
- cancer
- Prior art date
Links
- 230000001093 anti-cancer Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- WIFCKLPZYYALGY-UHFFFAOYSA-N 1h-pyrrole-2,3-dione Chemical class O=C1NC=CC1=O WIFCKLPZYYALGY-UHFFFAOYSA-N 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000022131 cell cycle Effects 0.000 abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract 2
- 230000037060 G2 phase arrest Effects 0.000 abstract 1
- 230000006978 adaptation Effects 0.000 abstract 1
- 238000011394 anticancer treatment Methods 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/50—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se proporcionan azol dionas sustituidas novedosas que eliminan células, suprimen la proliferación celular, suprimen el crecimiento celular, anulan el punto de control G2 del ciclo celular y/u ocasionan adaptación a la detención del ciclo celular en G2. Se proporcionan métodos para elaborar y usar los compuestos de la invención. La invención proporciona azol dionas sustituidas para tratar trastornos de proliferación celular. La invención incluye el uso de azol dionas sustituidas para eliminar o suprimir selectivamente células cancerosas sin tratamiento anticáncer adicional. La invención incluye el uso de azol dionas sustituidas que anulan el punto de control G2 del ciclo celular para sensibilizar selectivamente las células cancerosas a reactivos, tratamientos y/u otros tipos de reactivos anticáncer que dañan el ADN.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91125807P | 2007-04-11 | 2007-04-11 | |
| PCT/IB2008/003036 WO2009031040A2 (en) | 2007-04-11 | 2008-04-11 | Compounds with anti-cancer activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020009403A true MX2020009403A (es) | 2022-03-31 |
| MX391154B MX391154B (es) | 2025-03-21 |
Family
ID=39939984
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009403A MX391154B (es) | 2007-04-11 | 2008-04-11 | Compuestos con actividad anticancer |
| MX2015016591A MX374896B (es) | 2007-04-11 | 2008-04-11 | Compuestos con actividad anticáncer. |
| MX2009011025A MX2009011025A (es) | 2007-04-11 | 2008-04-11 | Compuestos con actividad anticancer. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015016591A MX374896B (es) | 2007-04-11 | 2008-04-11 | Compuestos con actividad anticáncer. |
| MX2009011025A MX2009011025A (es) | 2007-04-11 | 2008-04-11 | Compuestos con actividad anticancer. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8084454B2 (es) |
| EP (4) | EP3088397B1 (es) |
| JP (2) | JP5635396B2 (es) |
| KR (1) | KR101475311B1 (es) |
| CN (2) | CN105175394B (es) |
| AU (1) | AU2008294410B2 (es) |
| BR (2) | BRPI0810911B1 (es) |
| CA (4) | CA3188320A1 (es) |
| DK (2) | DK2152692T3 (es) |
| ES (3) | ES2927954T3 (es) |
| HU (2) | HUE029370T2 (es) |
| IL (4) | IL289165B2 (es) |
| MX (3) | MX391154B (es) |
| NZ (1) | NZ580237A (es) |
| RU (1) | RU2482111C2 (es) |
| WO (1) | WO2009031040A2 (es) |
| ZA (1) | ZA200906960B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3088397B1 (en) * | 2007-04-11 | 2019-04-10 | Canbas Co. Ltd. | Compounds that abrogate the cell cycle g2 checkpoint for use in the treatment of cancer |
| EP2304436A1 (en) | 2008-07-10 | 2011-04-06 | Nodality, Inc. | Methods for diagnosis, prognosis and treatment |
| EP2393488B1 (en) * | 2009-02-06 | 2019-06-19 | University Of Southern California | Therapeutic compositions comprising monoterpenes |
| US20100215644A1 (en) * | 2009-02-25 | 2010-08-26 | Nodality, Inc. A Delaware Corporation | Analysis of nodes in cellular pathways |
| EP2542082B8 (en) | 2010-03-03 | 2020-06-17 | Neonc Technologies Inc. | PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-perillyl alcohol |
| US20160038600A1 (en) | 2012-08-03 | 2016-02-11 | Neonc Technologies Inc. | Pharmaceutical compositions comprising poh derivatives |
| DK3685835T3 (da) | 2010-08-27 | 2025-07-21 | Univ Southern California | Farmaceutiske sammensætninger, der omfatter derivater af perillylalkohol |
| ES3056006T3 (en) | 2010-12-17 | 2026-02-17 | Univ Southern California | Methods and devices for using isoperillyl alcohol |
| WO2013020024A2 (en) * | 2011-08-03 | 2013-02-07 | Karyopharm Therapeutics, Inc. | Maleimide compounds and methods of treatment |
| US9814693B2 (en) | 2012-05-09 | 2017-11-14 | Delmar Pharmaceuticals, Inc. | Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies |
| IN2014MN02512A (es) | 2012-06-14 | 2015-07-17 | Daiichi Sankyo Co Ltd | |
| WO2014118186A1 (en) * | 2013-01-30 | 2014-08-07 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
| US9540462B2 (en) | 2014-12-05 | 2017-01-10 | Massachusetts Institute Of Technology | Catechol-rich polymers from N-substituted maleimides |
| FI3250550T3 (fi) | 2015-01-26 | 2023-07-17 | Ottawa Hospital Res Inst | Koostumuksia ja menetelmiä virusherkistymiseen |
| JP6674957B2 (ja) | 2015-02-12 | 2020-04-01 | ネオンク テクノロジーズ インク． | ペリリルアルコール誘導体を含む医薬組成物 |
| CN109071444A (zh) | 2016-03-16 | 2018-12-21 | 拜耳作物科学股份公司 | 作为农药和植物保护剂的n-(氰苄基)-6-(环丙基-羰基氨基)-4-(苯基)-吡啶-2-羧酰胺衍生物及相关化合物 |
| USD801721S1 (en) | 2016-03-31 | 2017-11-07 | Patricia Grayson Briden | Spooled item holding device |
| USD915100S1 (en) | 2016-03-31 | 2021-04-06 | Ocean 22, Llc | Spooled item holding device |
| TW201811766A (zh) | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
| JP2021512165A (ja) | 2018-01-29 | 2021-05-13 | コグノス・セラピューティクス・インコーポレイテッド | ボルテゾミブの腫瘍内送達 |
| MX2020007994A (es) | 2018-02-02 | 2020-09-09 | Boehringer Ingelheim Int | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
| WO2019149657A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors |
| CN111936125B (zh) | 2018-02-08 | 2025-03-04 | 南加州大学 | 穿透血脑屏障的方法 |
| DK4153599T3 (da) | 2020-05-22 | 2024-06-17 | Boehringer Ingelheim Int | Fremgangsmåde til at fremstille alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridin-carboxylat |
| ES2991340T3 (es) | 2020-05-22 | 2024-12-03 | Boehringer Ingelheim Int | Procedimiento continuo de fabricación de 7-amino-5-metil-[1,2,5]oxadiazolo[3,4-b]piridín-carboxilato de alquilo |
| EP4415700A4 (en) * | 2021-10-15 | 2025-12-24 | Univ Missouri | P1B TYPE ATPASES INHIBITORS |
| CN114425054A (zh) * | 2022-01-20 | 2022-05-03 | 中国人民解放军军事科学院军事医学研究院 | 一种蛋白酶体抑制剂Bortezomib在抗辐射损伤中的用途 |
| CN120247782B (zh) * | 2025-06-04 | 2025-08-19 | 北京颖泰嘉和生物科技股份有限公司 | 氟吡菌酰胺类化合物及其制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5564557A (en) * | 1978-11-08 | 1980-05-15 | Mitsui Toatsu Chem Inc | Diphenyl ether compound and herbicide containing the same |
| IL81307A0 (en) * | 1986-01-23 | 1987-08-31 | Union Carbide Agricult | Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives |
| US5635966A (en) * | 1994-01-11 | 1997-06-03 | Hewlett-Packard Company | Edge feed ink delivery thermal inkjet printhead structure and method of fabrication |
| JPH07224032A (ja) | 1994-02-09 | 1995-08-22 | Mitsui Petrochem Ind Ltd | Ｎ−アリールオキシフタルイミド誘導体、その製造方 法及びそれを有効成分として含有する除草剤 |
| JPH07244032A (ja) * | 1994-03-01 | 1995-09-19 | Ishikawajima Harima Heavy Ind Co Ltd | 溶接部検査装置 |
| CA2230896A1 (en) * | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
| US5935966A (en) * | 1995-09-01 | 1999-08-10 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
| CA2245029A1 (en) * | 1998-03-13 | 1999-09-13 | University Of British Columbia | Granulatimide compounds as g2 checkpoint inhibitors |
| US6205557B1 (en) | 1998-06-09 | 2001-03-20 | At&T Corp. | Redundant call processing |
| AU2093400A (en) * | 1998-11-24 | 2000-06-13 | Basf Aktiengesellschaft | Fungicides containing pyrrolidones as their active agents |
| JP4610828B2 (ja) | 1999-09-22 | 2011-01-12 | 株式会社 キャンバス | Ｇ２期細胞周期停止の阻害、およびｄｎａ損傷剤に対する細胞感作のための組成物および方法 |
| EP1257172B1 (de) | 2000-02-26 | 2004-10-13 | Basf Aktiengesellschaft | Fungizide mittel enthaltend als wirkstoffe pyrrolidone und deren verwendung bei der behandlung von pflanzen |
| JP2002318434A (ja) * | 2001-04-23 | 2002-10-31 | Konica Corp | ハロゲン化銀写真感光材料、処理方法、および画像形成方法 |
| FR2826653B1 (fr) * | 2001-06-29 | 2005-10-14 | Servier Lab | Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2003104181A2 (en) * | 2002-06-06 | 2003-12-18 | Canbas Co. Ltd. | Compounds that abrogate dna-damage-induced cell cycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments |
| WO2005024755A2 (en) * | 2002-12-31 | 2005-03-17 | Deciphera Pharmaceuticals, Llc. | Medicaments for the treatment of neurodegenerative disorders or diabetes |
| US7572816B2 (en) * | 2003-08-01 | 2009-08-11 | Auspex Pharmaceuticals, Inc. | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders |
| US7932281B2 (en) * | 2004-03-10 | 2011-04-26 | Kureha Corporation | Amine-based compound and use thereof |
| EP1730128A1 (en) * | 2004-03-31 | 2006-12-13 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| AU2006212951A1 (en) * | 2005-02-08 | 2006-08-17 | Merck & Co., Inc. | Inhibitors of checkpoint kinases |
| JP4976394B2 (ja) * | 2005-08-17 | 2012-07-18 | シェーリング コーポレイション | 新規な高親和性のキノリンベースのキナーゼリガンド |
| CA2627910A1 (en) * | 2005-11-01 | 2007-05-10 | Janssen Pharmaceutica N.V. | Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase |
| WO2007114338A1 (ja) * | 2006-03-31 | 2007-10-11 | Takeda Pharmaceutical Company Limited | 酸分泌抑制薬 |
| WO2008110891A2 (en) | 2007-03-09 | 2008-09-18 | Orchid Research Laboratories Limited, | New heterocyclic compounds |
| EP3088397B1 (en) | 2007-04-11 | 2019-04-10 | Canbas Co. Ltd. | Compounds that abrogate the cell cycle g2 checkpoint for use in the treatment of cancer |
-
2008
- 2008-04-11 EP EP16165912.3A patent/EP3088397B1/en active Active
- 2008-04-11 CA CA3188320A patent/CA3188320A1/en active Pending
- 2008-04-11 RU RU2009141619/04A patent/RU2482111C2/ru active
- 2008-04-11 CA CA2684037A patent/CA2684037C/en active Active
- 2008-04-11 BR BRPI0810911-7A patent/BRPI0810911B1/pt active IP Right Grant
- 2008-04-11 IL IL289165A patent/IL289165B2/en unknown
- 2008-04-11 JP JP2010502609A patent/JP5635396B2/ja active Active
- 2008-04-11 ES ES19167943T patent/ES2927954T3/es active Active
- 2008-04-11 NZ NZ580237A patent/NZ580237A/en unknown
- 2008-04-11 CA CA3030510A patent/CA3030510C/en active Active
- 2008-04-11 DK DK08829410.3T patent/DK2152692T3/en active
- 2008-04-11 CA CA2913840A patent/CA2913840C/en active Active
- 2008-04-11 MX MX2020009403A patent/MX391154B/es unknown
- 2008-04-11 EP EP22176177.8A patent/EP4074704A1/en not_active Withdrawn
- 2008-04-11 CN CN201510578313.XA patent/CN105175394B/zh active Active
- 2008-04-11 DK DK19167943.0T patent/DK3567035T3/da active
- 2008-04-11 AU AU2008294410A patent/AU2008294410B2/en active Active
- 2008-04-11 ES ES16165912T patent/ES2732230T3/es active Active
- 2008-04-11 HU HUE08829410A patent/HUE029370T2/hu unknown
- 2008-04-11 IL IL309201A patent/IL309201A/en unknown
- 2008-04-11 EP EP19167943.0A patent/EP3567035B1/en active Active
- 2008-04-11 BR BR122022005149-9A patent/BR122022005149B1/pt active IP Right Grant
- 2008-04-11 ES ES08829410.3T patent/ES2594704T3/es active Active
- 2008-04-11 US US12/082,643 patent/US8084454B2/en active Active
- 2008-04-11 WO PCT/IB2008/003036 patent/WO2009031040A2/en not_active Ceased
- 2008-04-11 CN CN200880019414A patent/CN101720323A/zh active Pending
- 2008-04-11 MX MX2015016591A patent/MX374896B/es unknown
- 2008-04-11 EP EP08829410.3A patent/EP2152692B9/en active Active
- 2008-04-11 KR KR1020097023566A patent/KR101475311B1/ko active Active
- 2008-04-11 MX MX2009011025A patent/MX2009011025A/es unknown
- 2008-04-11 HU HUE19167943A patent/HUE059861T2/hu unknown
-
2009
- 2009-10-06 ZA ZA2009/06960A patent/ZA200906960B/en unknown
- 2009-10-11 IL IL201380A patent/IL201380A0/en active IP Right Grant
-
2010
- 2010-11-19 US US12/950,297 patent/US8415357B2/en active Active
-
2013
- 2013-08-28 JP JP2013176324A patent/JP2014012706A/ja not_active Withdrawn
-
2015
- 2015-12-02 IL IL242883A patent/IL242883B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020009403A (es) | Compuestos con actividad anticancer. | |
| NL301145I2 (nl) | Tirbanibulin | |
| MX2020005463A (es) | Anticuerpos anti grupo de diferenciacion 47 (anti-cd47) y sus usos para tratar cancer. | |
| EA201000016A1 (ru) | Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями | |
| BRPI0808775A2 (pt) | compostos e composições como moduladores de atividade de gpr119 | |
| EA201071089A1 (ru) | Производные хиназолина как модуляторы raf-киназы и способы их применения | |
| PH12012502215A1 (en) | Anti-fgfr2 antibodies | |
| TR200906131T1 (tr) | Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e | |
| EA201171367A1 (ru) | Винилиндазолильные соединения | |
| EA201170521A1 (ru) | Новые соединения | |
| TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
| NO20084374L (no) | Imidazoltiazolforbindelser for behandling av sykdom | |
| EA200901074A1 (ru) | Лечение метастатической стадии рака предстательной железы дегареликсом | |
| SI1827441T1 (sl) | Kombinacije za zdravljenje bolezni, povezanih s celično proliferacijo | |
| EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| TNSN08382A1 (en) | New compounds | |
| TW200942552A (en) | Combination therapy with c-Met and HER antagonists | |
| BRPI0611670A2 (pt) | método para o tratamento ou prevenção de câncer em um indivíduo | |
| EA201270100A1 (ru) | Пиримидиноны в качестве ингибиторов pi3k | |
| EA201200473A1 (ru) | Замещенные (гетероарилметил)тиогидантоины | |
| EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| EA201070609A1 (ru) | Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств | |
| IN2012DN02471A (es) | ||
| EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| EA201201464A1 (ru) | Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний |